Takeda advances gene therapy, UK cancer biotech raises $83M, and new blood test may guide Wegovy use

A Cleveland‑based biotech announced that a previously halted gene therapy program has been revived, offering a potential new option for patients as the company pursues additional studies.

Takeda reported positive results from a combined Phase 2/3 trial, moving its investigational therapy closer to possible regulatory review.

In the United Kingdom, a cancer‑focused biotech secured $83 million in financing, strengthening its pipeline and development capabilities.

Researchers highlighted a blood‑based biomarker that could identify individuals most likely to benefit from the weight‑loss drug Wegovy, potentially improving treatment selection.

Separately, Viridian achieved another Phase 3 success for its thyroid eye disease candidate, while Ideaya announced the removal of two assets previously returned by GSK from its portfolio.